Millennium Management’s Aprea Therapeutics APRE Stock Holding History

Millennium Management’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,231	Closed	-$53K	–	6328
2022 Q4	$53K	Buy	8,231 +2,164	+36%	+$22.8K	﹤0.01%	5762
2022 Q3	$79K	Buy	6,067 +5,554	+1,083%	+$98.6K	﹤0.01%	6043
2022 Q2	$8K	Buy	+513	New	+$11.8K	﹤0.01%	6722
2021 Q3	–	Sell	-1,660	Closed	-$162K	–	6751
2021 Q2	$162K	Buy	+1,660	New	+$153K	﹤0.01%	6099
2021 Q1	–	Sell	-4,811	Closed	-$473K	–	5877
2020 Q4	$473K	Buy	4,811 +3,803	+377%	+$1.81M	﹤0.01%	4237
2020 Q3	$485	Sell	1,008 -8	-0.8%	-$4.48K	﹤0.01%	3595
2020 Q2	$788K	Buy	+1,016	New	+$667K	﹤0.01%	3132
2020 Q1	–	Sell	-317	Closed	-$291K	–	3815
2019 Q4	$291K	Buy	+317	New	+$175K	﹤0.01%	3677

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Millennium Management's APRE Position: Q1 2023 in Review

Millennium Management sold out of Aprea Therapeutics (APRE) in Q1 2023, closing a stake of 8,231 shares — an estimated $53K sold.

Millennium Management first reported a position in APRE in Q4 2019 and held it in 8 quarters. The position peaked at $788K in Q2 2020. 18 funds tracked by Wall St. Rank hold APRE as of Q1 2023.

Millennium Management reported no remaining Aprea Therapeutics position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 8,231 Aprea Therapeutics shares in Q1 2023, an estimated $53K.
Millennium Management first reported a position in Aprea Therapeutics in Q4 2019 and held it in 8 quarters.
Millennium Management's Aprea Therapeutics position peaked at $788K in Q2 2020.
18 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.